Title: An abnormal immediate increase in the intraocular pressure post-intravitreal injection in patients with Eales disease
Authors: Anya Lev, Oskana Vladimir, Olga Nikolai
DOI: https://dx.doi.org/10.18535/jmscr/v11i11.13
Abstract
Introduction
In 1880, British ophthalmologist Henry Eales described Eales' disease for the first time(1). Recurrent vitreous hemorrhaging is a hallmark of Eales' disease(2). The systemic anti- tuberculosis and the steroids usually control the disease and subsequently resolve the vitreous hemorrhage(3), but when the vitreous hemorrhage persists, anti-VEGF is an option(4).
References
- Eales Primary retinal hemorrhage in young men. Ophthalmic Review. 1882;1:41-6.
- Das T, Pathengay A, Hussain N, Biswas Eales’ disease: diagnosis and management. Eye. 2010;24(3):472-82.
- Abdullah Unilateral Eales disease with presumed tubercular etiology, three case reports. Health Science Journal. 2020;14(4):1-5.
- Patwardhan SD, Azad R, Shah BM, Sharma Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina. 2011;31(5):866-70.
- Abdullah A Novel Approach to Prevent Intraocular Pressure Spikes and Reflux During Intravitreal Injections.